0001104659-22-052778.txt : 20220429 0001104659-22-052778.hdr.sgml : 20220429 20220429070044 ACCESSION NUMBER: 0001104659-22-052778 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220429 DATE AS OF CHANGE: 20220429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRADIMED CORP CENTRAL INDEX KEY: 0001325618 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 731408526 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36534 FILM NUMBER: 22870048 BUSINESS ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 BUSINESS PHONE: 4076778022 MAIL ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 8-K 1 tm2213916d1_8k.htm FORM 8-K
0001325618 false 0001325618 2022-04-29 2022-04-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 29, 2022

 

Iradimed Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-36534   73-1408526
(Commission File Number)   (IRS Employer Identification No.)

 

1025 Willa Springs Dr., Winter Springs, FL   32708
(Address of principal executive offices)   (Zip Code)

 

(407) 677-8022

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol   Name of each exchange on which registered:
Common stock, par value $0.0001   IRMD   NASDAQ Capital Market

 

 

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On April 29, 2022, iRadimed Corporation issued a press release (the “Press Release”) announcing its financial results for the first quarter ended March 31, 2022. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d)            Exhibits

 

Exhibit No. Description
   
99.1 Press release dated April 29, 2022.
   
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IRADIMED CORPORATION
     
Date: April 29, 2022    
     
  By: /s/Matt Garner
  Name: Matt Garner
  Title: Controller and Interim Chief Financial Officer

 

 

 

 EX-99.1 2 tm2213916d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

IRADIMED CORPORATION Announces First Quarter 2022 Financial Results

 

●Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22

●Announces second quarter 2022 financial guidance

●Increases full-year 2022 financial guidance

 

Winter Springs, Florida, April 29, 2022 – iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

 

“I am very satisfied with these results. Having the first quarter start off strongly shows the continued strength of our business. Our growth afforded us the opportunity to pay a special dividend of $1.00 per share during the first quarter. Our expectation is to continue building momentum, as shown in the demand for our products, which remains at record levels. This gives us the confidence to increase our outlook for the full year. We are now expecting revenue of $52.5 million to $53.2 million and non-GAAP earnings per share of $0.96 to $1.03,” said Roger Susi, President and Chief Executive Officer of the Company.

 

For the first quarter ended March 31, 2022, the Company reported revenue of $12.3 million compared to $9.2 million for the first quarter 2021. Net income was $2.5 million, or $0.20 per diluted share, compared to $1.4 million, or $0.11 per diluted share for the first quarter 2021.

 

Non-GAAP net income was $2.8 million, or $0.22 per diluted share, for the quarter ended March 31, 2022, and excludes $0.3 million of stock compensation expense, net of tax expense. Non-GAAP net income for the quarter ended March 31, 2021 was $1.6 million, or $0.13 per diluted share, and excludes $0.3 million of stock compensation expense, net of tax.

 

Revenue Information:

 

   Three Months Ended
March 31,		 
   2022   2021 
Devices:        
MRI compatible IV infusion pump system   $3,281,939   $3,503,347 
MRI compatible patient vital signs monitoring systems    5,194,751    2,603,830 
Total Devices revenue    8,476,690    6,107,177 
Disposables, services and other    3,318,902    2,635,466 
Amortization of extended warranty agreements    515,118    481,353 
Total revenue   $12,310,710   $9,223,996 

 

For the first quarter 2022, domestic sales were 81.1 percent of total revenue, compared to 78.8 percent for the first quarter 2021. Gross profit margin was 76.2 percent for the first quarter 2022, compared to 76.6 percent for the first quarter 2021.

 

 

 

 

Cash Flow:

 

For the three months ended March 31, 2022, cash from operations was $1.4 million, compared to $0.9 million for the same period in 2021.

 

Financial Guidance

 

For the second quarter 2022, the Company expects to report revenue of $12.5 million to $12.7 million, GAAP diluted earnings per share of $0.21 to $0.23, and non-GAAP diluted earnings per share of $0.23 to $0.25.

 

The Company increased its full year 2022 financial guidance and now expects to report revenue of $52.5 million to $53.2 million, GAAP diluted earnings per share of $0.89 to $0.95, and non-GAAP diluted earnings per share of $0.96 to $1.03. The Company previously expected revenue of $51.4 million to $52.2 million, GAAP diluted earnings per share of $0.82 to $0.90, and non-GAAP diluted earnings per share of $0.91 to $1.01, which assumes a normalized tax rate compared to 2021.

 

The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be approximately $1.4 million and $0.3 million for the full year and second quarter 2022, respectively.

 

Use of non-GAAP Financial Measures

 

The Company believes the use of non-GAAP net income, free cash flow and infrequent income tax items are helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with U.S. GAAP.

 

We calculate non-GAAP net income as net income excluding (1) stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period; (2) operating expenses, net of tax, that we believe are not indicative of the Company’s on-going core operating performance, and; (3) infrequent tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes. We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for purchases of property and equipment.

 

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our shareholders through various means.

 

All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our on-going core operating results.

 

A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of cash flows. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with U.S. GAAP and are not indicative of net income or cash provided by operating activities.

 

 

 

 

Conference Call

 

iRadimed has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today, April 29, 2022. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering the reservation code 3179386.

 

The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.

 

About iRadimed Corporation

 

iRadimed Corporation is a leader in the development of innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We develop, manufacture, market and distribute MRI compatible medical devices and accessories, disposables and services relating to them.

 

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

 

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

 

For more information please visit www.iradimed.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements (i.e., statements which are not historical facts). Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic, including the impact of existing and new variants, and measures taken in response; potential disruptions in our limited supply chain for our products; the Company’s ability to receive FDA 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.

 

 

 

 

IRADIMED CORPORATION 

CONDENSED BALANCE SHEETS

 

   March 31,
2022		   December 
31,2021		 
    (unaudited)      
ASSETS          
Current assets:          
Cash and cash equivalents   $50,446,484   $61,999,550 
Investments    500,090    501,855 
Accounts receivable, net    6,513,061    5,136,599 
Inventory, net    4,345,042    4,299,799 
Prepaid expenses and other current assets    1,020,398    1,000,716 
Prepaid income taxes    2,689,237    3,306,438 
Total current assets    65,514,312    76,244,957 
Property and equipment, net    2,149,754    2,069,376 
Intangible assets, net    1,334,670    1,118,584 
Operating lease right-of-use asset    2,414,472    2,482,084 
Deferred income taxes, net    808,019    765,096 
Other assets    172,272    201,325 
Total assets   $72,393,499   $82,881,422 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   $1,136,651   $782,903 
Accrued payroll and benefits    1,877,475    2,814,560 
Other accrued taxes    122,461    140,315 
Warranty reserve    106,733    108,880 
Deferred revenue    2,586,776    2,553,096 
Current portion of operating lease liability    280,698    276,568 
Other current liability    138,441    146,435 
Total current liabilities    6,249,235    6,822,757 
Deferred revenue    1,462,055    1,679,343 
Operating lease liability    2,133,774    2,205,516 
Total liabilities    9,845,064    10,707,616 
Stockholders’ equity:          
Common stock    1,256    1,254 
Additional paid-in capital    25,618,544    25,160,618 
Retained earnings    36,922,508    46,994,922 
Accumulated other comprehensive income    6,127    17,012 
Total stockholders’ equity    62,548,435    72,173,806 
Total liabilities and stockholders’ equity   $72,393,499   $82,881,422 

 

 

 

 

IRADIMED CORPORATION 

CONDENSED STATEMENTS OF OPERATIONS 

(Unaudited)

 

   For the Three Months Ended
March 31,		 
   2022   2021 
Revenue   $12,310,710   $9,223,996 
Cost of revenue    2,931,186    2,161,680 
Gross profit    9,379,524    7,062,316 
Operating expenses:          
General and administrative    2,715,950    2,430,369 
Sales and marketing    3,069,556    2,379,124 
Research and development    519,095    475,817 
Total operating expenses    6,304,601    5,285,310 
Income from operations    3,074,923    1,777,006 
Other expense, net    (14,915)   (5,663)
Income before provision for income taxes    3,060,008    1,771,343 
Provision for income tax expense    573,295    384,494 
Net income   $2,486,713   $1,386,849 
Net income per share:          
Basic   $0.20   $0.11 
Diluted   $0.20   $0.11 
Weighted average shares outstanding:          
Basic    12,552,817    12,310,577 
Diluted    12,655,518    12,521,279 

 

 

 

 

IRADIMED CORPORATION 

CONDENSED STATEMENTS OF CASH FLOWS 

(Unaudited)

 

   Three Months Ended 
   March 31, 
   2022   2021 
Operating activities:          
Net income   $2,486,713   $1,386,849 
Adjustments to reconcile net income to net cash provided by operating activities:          
Change in allowance for doubtful accounts    4,219    1,728 
Change in provision for excess and obsolete inventory    12,254    (1,992)
Depreciation and amortization    433,925    331,794 
Gain on disposal of property and equipment    (4,894)   — 
Stock-based compensation    453,360    347,741 
Deferred income taxes, net    (52,043)   288,895 
Changes in operating assets and liabilities:          
Accounts receivable    (1,380,681)   9,032 
Inventory    82,909    (668,361)
Prepaid expenses and other current assets    (369,791)   (560,508)
Other assets    39,481    32,059 
Accounts payable    186,340    (75,805)
Accrued payroll and benefits    (937,085)   (482,099)
Other accrued taxes    (17,854)   (26,388)
Warranty reserve    (2,147)   6,394 
Deferred revenue    (117,726)   250,359 
Other current liability    (7,994)   — 
Prepaid income taxes    617,201    103,383 
Net cash provided by operating activities    1,426,187    943,081 
Investing activities:          
Purchases of property and equipment    (183,352)   (132,318)
Capitalized intangible assets    (241,342)   (41,615)
Net cash used in investing activities    (424,694)   (173,933)
Financing activities:          
Dividends paid    (12,559,127)   — 
Proceeds from exercises of stock options    71,948    2,460 
Taxes paid related to the net share settlement of equity awards    (67,380)   (38,707)
Net cash used in financing activities    (12,554,559)   (36,247)
Net (decrease) increase in cash and cash equivalents    (11,553,066)   732,901 
Cash and cash equivalents, beginning of period    61,999,550    50,068,728 
Cash and cash equivalents, end of period   $50,446,484   $50,801,629 

 

 

 

 

IRADIMED CORPORATION 

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (UNAUDITED) 

 

Non-GAAP Net Income and Diluted EPS

 

   Three Months Ended
March 31,		 
   2022   2021 
Net income   $2,486,713   $1,386,849 
Excluding:          
Stock-based compensation expense, net of tax expense    340,473    262,809 
Non-GAAP net income   $2,827,186   $1,649,658 
Weighted-average shares outstanding – diluted    12,655,518    12,521,279 
Non-GAAP net income per share – diluted   $0.22   $0.13 

 

Free Cash Flow

 

   Three Months Ended
March 31,		 
   2022   2021 
Net cash provided by operating activities   $1,426,187   $943,081 
Less:          
Purchases of property and equipment    183,352    132,318 
Free cash flow   $1,242,835   $810,763 

 

Media Contact: 

iRadimed Corporation 

(407) 677-8022 

InvestorRelations@iradimed.com

 

 

 

 EX-101.SCH 3 irmd-20220429.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 irmd-20220429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 irmd-20220429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2213916d1_ex99-1img001.jpg GRAPHIC begin 644 tm2213916d1_ex99-1img001.jpg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
  •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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
    Cover
    Apr. 29, 2022
    Cover [Abstract]  
    Document Type 8-K
    Amendment Flag false
    Document Period End Date Apr. 29, 2022
    Entity File Number 001-36534
    Entity Registrant Name Iradimed Corporation
    Entity Central Index Key 0001325618
    Entity Tax Identification Number 73-1408526
    Entity Incorporation, State or Country Code DE
    Entity Address, Address Line One 1025 Willa Springs Dr.
    Entity Address, City or Town Winter Springs
    Entity Address, State or Province FL
    Entity Address, Postal Zip Code 32708
    City Area Code 407
    Local Phone Number 677-8022
    Written Communications false
    Soliciting Material false
    Pre-commencement Tender Offer false
    Pre-commencement Issuer Tender Offer false
    Title of 12(b) Security Common stock, par value $0.0001
    Trading Symbol IRMD
    Security Exchange Name NASDAQ
    Entity Emerging Growth Company false
    XML 8 tm2213916d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001325618 2022-04-29 2022-04-29 iso4217:USD shares iso4217:USD shares 0001325618 false 8-K 2022-04-29 Iradimed Corporation DE 001-36534 73-1408526 1025 Willa Springs Dr. Winter Springs FL 32708 407 677-8022 false false false false false Common stock, par value $0.0001 IRMD NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://iradimed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2213916d1_8k.htm irmd-20220429.xsd irmd-20220429_lab.xml irmd-20220429_pre.xml tm2213916d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2213916d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2213916d1_8k.htm" ] }, "labelLink": { "local": [ "irmd-20220429_lab.xml" ] }, "presentationLink": { "local": [ "irmd-20220429_pre.xml" ] }, "schema": { "local": [ "irmd-20220429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "irmd", "nsuri": "http://iradimed.com/20220429", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2213916d1_8k.htm", "contextRef": "From2022-04-29to2022-04-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://iradimed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2213916d1_8k.htm", "contextRef": "From2022-04-29to2022-04-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://iradimed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-052778-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-052778-xbrl.zip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end